In conclusion, we have provided evidence for the value of targeting key proteins of the PI3K/Akt and Wnt/β-catenin pathways and their prognostic implications for developing new directed therapies and improve outcomes in CRC treatment. The gene discussed is AKT1; the disease is colorectal carcinoma.